HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAC In US Supplements: Enforcement Discretion Continues, Open Sign Posted On Rulemaking Door

Executive Summary

Final guidance on NAC use in supplements continue FDA's enforcement discretion as agency also notes potential for rulemaking deeming the ingredient a lawful dietary ingredient. But three to five years for a rulemaking is too long, especially when FDA already knows NAC is safe in supplements, industry says.

You may also be interested in...

Consumer Health Products Claiming Treatments For Moles, COVID-19 Back On US FDA Warning Radar

Product sold on Amazon among topical remedies for mole and skin tag removal back on US regulatory radar. Recent warnings show violative COVID-19 claims haven’t disappeared and supplement GMP problems remain common.

It’s Official: US Enforcement Discretion For NAC In Supplements, And Regulatory Options For FDA

Draft guidance states enforcement discretion allowing sales of N-acetyl-L-cysteine supplements which FDA in 2020 ordered firms to halt selling due to its use as a drug ingredient. However, NAC supplements, as they have remained since 2020, were available to US consumers when draft was published.

NAC Gains Tentative Safety Clearance As US Industry Contests FDA's Attempt To Remove It

FDA answers reach supplement industry sounding like a siren that the agency may take same enforcement step it has with NAC with other ingredients long used in supplements. Answers also might not be enough to convince firms to return NAC-containing supplements to their lineups.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts